Skip to main content
. Author manuscript; available in PMC: 2018 May 30.
Published in final edited form as: Circulation. 2017 Feb 21;135(22):2091–2101. doi: 10.1161/CIRCULATIONAHA.116.024436

Figure 1. Incident Coronary Heart Disease Events by Statin Therapy and Genetic Risk Group in WOSCOPS.

Figure 1

Nonfatal myocardial infarction or death from coronary heart disease rate by randomized treatment group and polygenic risk group in the WOSCOPS trial. Absolute events (and percentage) per individuals in each group is shown at the bottom of the bars. This represents 604 events over 64,031 total patient-years of follow up. The follow up period was 4.8 years (SD 0.7 years) within the trial for both placebo and statin groups, and out of trial was 8.1 years (SD 3.4 years) in the placebo group and 8.4 years (SD 3.0 years) in the statin-treated group.